The peptide promotes angiogenesis, the formation of new blood vessels that deliver nutrients and oxygen to injured tissues
The pharmacokinetics are clear: tesofensine reaches maximum plasma concentration (Tmax) 34 hours after oral administration regardless of time of day, but the compound's extraordinarily long half-life means this initial peak is less clinically relevant than the cumulative plasma buildup over the first two weeks
Sikiric et al., 2018), along with the evidence that pentadecapeptide BPC 157 may prevent and/or attenuate or eliminate, thus, counteract both developing and already formed both arterial thrombosis (Hrelec et al., 2009
Dose increase: at Day 16 inside the on phase, the dose steps from the low end to the high end of the range
Your compounding pharmacy documentation will specify the exact beyond-use date
Understanding the full range of ghk-cu benefits alongside core nad+ benefits makes this clearer